PART a: IDENTIFICATION OF R&D Result
· The project team
SECTION I: ESTIMATION OF COSTS
|
1 |
Taking into account the rest of the cost evaluation please provide an overall estimation of the total costs for full deployment/production of the R & D result. |
| … in terms of IPR protection | |
| The patent family is based on patent application publication number WO2008HU00028 20080307. The European national phase is currently in progress.
|
|
| …in terms of product development | |
| Two senior professionals and two technicians will work three year’s on it. 150.000 EUR
|
|
| …in terms of mass production | |
|
|
|
| … in terms of marketing | |
|
2 |
Based on the above assessment as well as the marketing information please provide the correct estimation of the price for R&D product in correlation with costs |
|||||
|
|
Year 1 |
Year 2 |
Year 3 |
Year 4 |
Year 5 |
|
|
Fixed costs |
|
|
|
|
|
|
|
Personnel |
|
|
|
|
|
|
|
Other running costs |
|
|
|
|
|
|
|
Marketing costs |
|
|
|
|
|
|
|
TOTAL EXPECTED COSTS |
|
|
|
|
|
|
|
Price per Unit |
|
|
|
|
|
|
|
Type of Unit |
|
|||||
|
Number of Units |
|
|
|
|
|
|
|
TOTAL Expected Revenues |
|
|
|
|
|
|
|
CASH FLOW REQUIRED (REVENUES-COSTS) |
|
|
|
|
|
|
|
TOTAL CAPITAL required for five years |
|
|||||
SECTION 2: QUALITATIVE FACTORS
|
3 |
Dimension of identified target groups |
|
|
|
|
4 |
Evaluation of financial Risks for R&D result |
| The invention is good, for other proteins too, but this should start from the beginning of the work. The university has all the necessary instrumentation for it.
It requires a further three year development to reach the industrial technology for this solution. It has high risk.
|
|
SECTION 3: IDENTIFICATION OF FINANCING SOURCES
After evaluating all the above mentioned criteria, please tick the best financing source for the achievement of R&D result (i.e. own capitals, banking credits, venture capital, business angels, etc)
|
1. European Funding Define relevance of the product with the following potential funding sources and comment |
|
1. … 2. … 3. … 4. … |
|
2. National Funding |
|
1. … 2. … 3. … … |
|
3. Private funding |
2. … 3. … … |
|
4. Other |
|
|
SECTION 3: FINAL EVALUATION
| It is requested a final evaluation considering the funding opportunities you believe most suitable for the exploitation of the R&D result, considering the possibility of the creation of a spin-off, further research, in particular, a cost/benefit analysis and a financial projection for the R&D result, type of collaboration identified (i.e. Licensing Agreement, Technical Cooperation, Joint Venture, Manufacturing Agreement, Commercial Agreement with Technical Assistance, Creation of a spin-off, Joint further development)… |
| The invention is a novel method of core-shell nanoparticle preparation of protein drugs or protein-bound active compounds, which provides a relatively easy and inexpensive way to formulate sustained release products.
Benefits of the novel method of core-shell nanoparticle preparation of protein drugs or protein-bound active compounds: ‒ provides a relatively easy method ‒ provides a relatively inexpensive method ‒ particles are in the nano size range ‒ sustained release benefits for patients (avoiding sudden large concentration, rare dosage, improved effects, and comfort) ‒ economical (installation efficiency of the protein drug superior to that of infiltration method)
Industrial-scale manufacturing is in progress. They are looking for producers and/or a product developer to acquire the patent rights through an in-licence agreement. |
Decision of evaluation (Please keep only the appropriate)
- The R&D has a high potential of exploitation
Tivadar Lippényi
